Livio Trusolino
Livio Trusolino
Professor, University of Torino School of Medicine, Italy
Verified email at ircc.it - Homepage
TitleCited byYear
MET signalling: principles and functions in development, organ regeneration and cancer
L Trusolino, A Bertotti, PM Comoglio
Nature reviews Molecular cell biology 11 (12), 834, 2010
8932010
Drug development of MET inhibitors: targeting oncogene addiction and expedience
PM Comoglio, S Giordano, L Trusolino
Nature reviews Drug discovery 7 (6), 504, 2008
7732008
Scatter-factor and semaphorin receptors: cell signalling for invasive growth
L Trusolino, PM Comoglio
Nature Reviews Cancer 2 (4), 289, 2002
7702002
Patient-derived xenograft models: an emerging platform for translational cancer research
M Hidalgo, F Amant, AV Biankin, E Budinská, AT Byrne, C Caldas, ...
Cancer discovery 4 (9), 998-1013, 2014
6262014
A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer
A Bertotti, G Migliardi, F Galimi, F Sassi, D Torti, C Isella, D Corŕ, ...
Cancer discovery 1 (6), 508-523, 2011
5802011
A signaling adapter function for α6β4 integrin in the control of HGF-dependent invasive growth
L Trusolino, A Bertotti, PM Comoglio
Cell 107 (5), 643-654, 2001
4822001
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ...
Cancer discovery 3 (6), 658-673, 2013
4332013
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of …
A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ...
The Lancet Oncology 17 (6), 738-746, 2016
3042016
Stromal contribution to the colorectal cancer transcriptome
C Isella, A Terrasi, SE Bellomo, C Petti, G Galatola, A Muratore, A Mellano, ...
Nature genetics 47 (4), 312, 2015
3022015
Hypertension-associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport.
G Tripodi, F Valtorta, L Torielli, E Chieregatti, S Salardi, L Trusolino, ...
The Journal of clinical investigation 97 (12), 2815-2822, 1996
2981996
The Met tyrosine kinase receptor in development and cancer
A Gentile, L Trusolino, PM Comoglio
Cancer and Metastasis Reviews 27 (1), 85-94, 2008
2832008
Interactions between growth factor receptors and adhesion molecules: breaking the rules
PM Comoglio, C Boccaccio, L Trusolino
Current opinion in cell biology 15 (5), 565-571, 2003
2532003
Series Introduction: Invasive growth: from development to metastasis
PM Comoglio, L Trusolino
The Journal of clinical investigation 109 (7), 857-862, 2002
2422002
The genomic landscape of response to EGFR blockade in colorectal cancer
A Bertotti, E Papp, S Jones, V Adleff, V Anagnostou, B Lupo, M Sausen, ...
Nature 526 (7572), 263, 2015
2212015
Interrogating open issues in cancer precision medicine with patient-derived xenografts
AT Byrne, DG Alférez, F Amant, D Annibali, J Arribas, AV Biankin, A Bruna, ...
Nature Reviews Cancer 17 (4), 254, 2017
1892017
Oncogene addiction as a foundational rationale for targeted anti‐cancer therapy: promises and perils
D Torti, L Trusolino
EMBO molecular medicine 3 (11), 623-636, 2011
1862011
Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3
C Sun, S Hobor, A Bertotti, D Zecchin, S Huang, F Galimi, F Cottino, ...
Cell reports 7 (1), 86-93, 2014
1632014
HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity
L Trusolino, S Cavassa, P ANGELINI, M ANDÒ, A Bertotti, PM COMOGLIO, ...
The FASEB Journal 14 (11), 1629-1640, 2000
1512000
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas
G Migliardi, F Sassi, D Torti, F Galimi, ER Zanella, M Buscarino, D Ribero, ...
Clinical Cancer Research 18 (9), 2515-2525, 2012
1412012
β4 integrin activates a Shp2–Src signaling pathway that sustains HGF-induced anchorage-independent growth
A Bertotti, PM Comoglio, L Trusolino
J Cell Biol 175 (6), 993-1003, 2006
1382006
The system can't perform the operation now. Try again later.
Articles 1–20